1. Research topic: Health economics of biological agents in Australia.
- Author
-
Wang, Li‐Chin, Collins, Glen, Corte, Crispin, Katelaris, Peter, and Leong, Rupert
- Subjects
- *
INFLIXIMAB , *INFLAMMATORY bowel disease treatment , *COLITIS treatment , *ULCERATIVE colitis , *MEDICAL care costs , *TUMOR necrosis factors - Abstract
The article explores national and state-based use and cost of infliximab (IFX) and adalimubab (ADA) for treatment of luminal and fistulizing Crohn's disease and acute severe ulcerative colitis under the Pharmaceutical Benefits Scheme (PBAC) between January 2007 and July 2014. Topics discussed include the exponential increase in IFX and ADA usage while still remaining within PBAC projections and marked geographical heterogeneity in anti-tumor necrosis factor usage.
- Published
- 2016
- Full Text
- View/download PDF